Redigerer CureVac COVID-19-vaksine

'''CureVac COVID-19-vaksine''' er en [[covid-19-vaksine]]kandidat utviklet av [[CureVac|CureVac N.V.]] oge [[Coalition for Epidemic Preparedness Innovations]] (CEPI).<ref>{{cite press release | title=CureVac focuses on the development of mRNA-based coronavirus vaccine to   protect people worldwide | website=CureVac | date=15. mars 2020 | url=https://www.curevac.com/en/2020/03/15/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide/ | access-date=17. februar 2021}}</ref> I april 2021 var den på Fase III-stadiet av kliniske undersøkelser. Produsenten marketsføer vaksinen under navnet '''CVnCoV'''<ref name="cvncovname">{{cite press release | title=Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV | website=CureVac | date=30. mars 2021 | url=https://www.curevac.com/en/2021/03/30/celonic-and-curevac-announce-agreement-to-manufacture-over-100-million-doses-of-curevacs-covid-19-vaccine-candidate-cvncov/ | access-date=14. april 2021}}</ref>.

== Teknologi ==
CVnCoV er en [[RNA-basert vaksine|mRNA-vaksine]] som koder en minimal bit av [[coronavirus]]ets [[spikeprotein]], og aktiverer kroppens [[immunsystem]] mot dette.<ref name="schlake">{{cite journal|vauthors=Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ|date=November 2012|title=Developing mRNA-vaccine technologies|journal=RNA Biology|volume=9|issue=11|pages=1319–30|doi=10.4161/rna.22269|pmc=3597572|pmid=23064118}}</ref><ref name="cdc">{{cite web |title=Understanding mRNA COVID-19 vaccines |url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html |publisher=US Centers for Disease Control and Prevention |access-date=5. januar 2021 |date=18. desember 2020}}</ref> CVnCoVs teknologi interagere ikke med det menneskelige [[genom]].<ref name=schlake/>

CVnCoV benytter umodifisert RNA,<ref name=":3">{{Cite web|title=COVID-19|url=https://www.curevac.com/en/covid-19/|access-date=2020-12-21|publisher=CureVac}}</ref> til forskjell fra [[Pfizer–BioNTech COVID-19-vaksine]]n og [[Moderna COVID-19-vaksine]]s, som begge benytter [[nukleosidmodifidert messenger-RNA|nukleosidmodifisert RNA]].<ref>{{Cite journal|last=Dolgin|first=Elie|date=2020-11-25|title=COVID-19 vaccines poised for launch, but impact on pandemic unclear|journal=Nature Biotechnology|pages=d41587–020–00022-y|doi=10.1038/d41587-020-00022-y|pmid=33239758|s2cid=227176634}}</ref>

Produsenten markedsfører for tiden (april 2021) vaksinen under navnet CVnCoV<ref name=cvncovname/>. '''Zorecimeran''' er det foreslåtte [[INN-klassifikasjon|internasjonale ikkenproprietære navn]] (pINN).<ref name="INN">{{cite journal | vauthors=((World Health Organization)) | title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition) | journal=WHO Drug Information |date=Oktober 2020 | volume=34 | issue=3 | pages=668–69 |url=https://www.who.int/medicines/publications/druginformation/issues/WHO_DI_34-3_PL124-SpecialEdition.pdf | archive-date=27. november 2020 | archive-url=https://web.archive.org/web/20201127075410/https://www.who.int/medicines/publications/druginformation/issues/WHO_DI_34-3_PL124-SpecialEdition.pdf | url-status=live }}</ref>

== Referanser ==
<references />

== Eksterne lenker ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/zorecimeran | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Zorecimeran }}

{{Autoritetsdata}}

[[Kategori:Covid-19-vaksiner]]
[[Kategori:Koronavirus vaksinearbeid]]
[[Kategori:RNA-vaksiner]]